Kalaris Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Kalaris Therapeutics Inc.
Former names: Allovir, Inc. ViraCyte, Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation: Delaware
Headquarters city: Berkeley Heights
Headquarters state / province: New Jersey
Headquarters country: United States
Fiscal year end: December
Ticker symbol: KLRS
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001754068
EIN: 83-1971007

Board of directors

Follow this board

Andrew Oxtoby · Director · See Remarks
Since 2025
Anthony P. Adamis · Director
Since 2025
David Hallal · Director
Since 2023
Derek N. Adams · Director
Since 2023
Diana Brainard · Director · Chief Executive Officer
Since 2023
Jeffrey S. Bornstein · Director
Since 2023
Juan Vera · Director
Since 2023
Laurie Keating · Director
Since 2026
Leone D. Patterson · Director
Since 2025
Malcolm Brenner · Director
Since 2023
Michael Dybbs · Director
Since 2025
Morana Jovan-Embiricos · Director
Since 2023
Napoleone Ferrara · Director
Since 2025
Samir Chandrakant Patel · Director
Since 2025
Shawn Tomasello · Director
Since 2023
Srinivas Akkaraju · Director Overboarded
Since 2025
Vikas Sinha · Director · See Remarks
Since 2023

Chief executives

Diana Brainard · Chief Executive Officer

Dates unknown

Director election results

Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

10 of this board's directors also sit on 17 other boards. 14 are in the same sector.

Shared director Other board Same sector +1 more in the list below

Nkarta Inc. Same sector
via Leone D. Patterson and Michael Dybbs
Scholar Rock Holding Corporation Same sector
via David Hallal and Srinivas Akkaraju
4D Molecular Therapeutics Inc. Same sector
via Shawn Tomasello
Alumis Inc. Same sector
via Srinivas Akkaraju
Cabaletta Bio Inc. Same sector
via Shawn Tomasello
Eos Energy Enterprises Inc.
via Jeffrey S. Bornstein
EyePoint Inc.
via Anthony P. Adamis
Immuneering Corporation Same sector
via Laurie Keating
Marker Therapeutics Inc. Same sector
via Juan Vera
Mineralys Therapeutics Inc. Same sector
via Srinivas Akkaraju
Nektar Therapeutics Same sector
via Diana Brainard
PepGen Inc. Same sector
via Laurie Keating
Quince Therapeutics Inc. Same sector
via Leone D. Patterson
Seer Inc.
via David Hallal
SpyGlass Pharma Inc. Same sector
via Michael Dybbs
Sutro Biopharma Inc. Same sector
via Michael Dybbs
vTv Therapeutics Inc. Same sector
via Srinivas Akkaraju

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $6,179,975; 2 purchases by 1 insider
Sold, last 12 months: $12,869; 1 sale by 1 insider

Date	Insider	Transaction	Shares	Price	Value
May 20, 2026	Srinivas Akkaraju Director, 10% owner	Open-market purchase	+244,300	$4.83	$1,179,969
May 20, 2026	Srinivas Akkaraju Director, 10% owner	Other	−66,906	—	—
May 20, 2026	Srinivas Akkaraju Director, 10% owner	Other	+14,937	—	—
May 20, 2026	Srinivas Akkaraju Director, 10% owner	Other	+4,471	—	—
Mar 20, 2026	Hagen Brett R Officer (Chief Accounting Officer)	Open-market sale	−1,915	$6.72	$12,869
Dec 22, 2025	Srinivas Akkaraju Director, 10% owner	Grant or award	+1,500,000	$10.00	$15,000,000
Dec 18, 2025	Srinivas Akkaraju Director, 10% owner	Open-market purchase	+479,847	$10.42	$5,000,006
Mar 26, 2025	Hagen Brett R Officer (Chief Accounting Officer)	Open-market sale	−907	$8.97	$8,136
Mar 18, 2025	Napoleone Ferrara Director	Grant or award	+504,000	—	—
Mar 18, 2025	Samir Chandrakant Patel Director	Grant or award	+252,000	—	—
Mar 18, 2025	Feinsod Matthew Officer (Chief Medical Officer)	Grant or award	+4,030	—	—
Mar 18, 2025	Srinivas Akkaraju Director, 10% owner	Grant or award	+11,444,503	—	—
Mar 18, 2025	Samir Chandrakant Patel Director	Grant or award	+100,800	—	—
Feb 21, 2025	Vikas Sinha Director, Officer (See Remarks), 10% owner	Open-market sale	−303	$10.08	$3,054
Feb 21, 2025	Hagen Brett R Officer (Chief Accounting Officer)	Open-market sale	−96	$10.08	$968

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Kalaris Therapeutics Inc.

Who is the CEO of Kalaris Therapeutics Inc.?

Diana Brainard is Kalaris Therapeutics Inc.'s Chief Executive Officer.

How many directors are on Kalaris Therapeutics Inc.'s board?

Kalaris Therapeutics Inc.'s board has 17 directors: Andrew Oxtoby, Anthony P. Adamis, David Hallal, Derek N. Adams, Diana Brainard, Jeffrey S. Bornstein, Juan Vera, Laurie Keating, Leone D. Patterson, Malcolm Brenner and 7 others.

Are Kalaris Therapeutics Inc. insiders buying or selling shares?

Over the last 12 months, Kalaris Therapeutics Inc. insiders bought $6.2 million of shares in 2 purchases and sold $12,869 of shares in 1 sale on the open market, as reported to the SEC on Forms 4 and 5.

How is Kalaris Therapeutics Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="kalaris-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.